Opinion|Videos|November 26, 2024
Beyond Hot Flashes: The Importance of Sleep in Menopause Management
Key Takeaways
- Sleep disturbances in menopause are independent symptoms, impacting mood, cardiovascular health, and Alzheimer's risk.
- Elinzanetant may improve sleep quality in menopausal women, addressing a critical aspect of menopause management.
Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data from the NIRVANA trial], how important is it to address sleep as part of menopause management, even in the absence of vasomotor symptoms, and how is sleep quality linked to other complications such as mood disorders, cardiovascular disease, and Alzheimer disease?
- What role do you anticipate elinzanetant to have in this space?
- (FIFFICK) How do you anticipate the treatment paradigm of VMS associated with menopause to shift with the advent of these new neurokinin-targeted therapies?
- Please discuss your thoughts on whether they’ll become a new standard of care, and if you anticipate them being used as monotherapy vs combination therapy.
Advertisement
Related to this article
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
2
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
3
New Mechanism of DME Treatment Highlights Clinical Trial Updates
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5